Paul J. Hesketh MD

Oncology•Burlington, MA

Chair, Lahey Health Cancer Institute and Professor, Medicine, Tufts Medical Center

Join to View Full Profile

Mall Rd# 41Burlington, MA 01805
Phone+1 781-744-8400
Fax+1 781-744-5245

Summary

I am a board certified oncologist and Chair of Lahey Health Cancer Institute in Burlington, Massachusetts.

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1983
St Elizabeth's Medical CenterResidency, Internal Medicine, 1978 - 1981
Uconn School Of MedicineClass of 1978

Certifications & Licensure

NH State Medical License 2024 - 2026
MA State Medical License 1980 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Boston Magazine Castle Connolly, 2010-2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 2
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy Start of enrollment: 2008 Apr 01
Completed
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network Start of enrollment: 2010 Nov 01
Terminated
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
ACTIVE_NOT_RECRUITING
PHASE3
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

11 citations
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport
Supportive Care in Cancer. 2023-12-22
13 citations
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Florian Scotté, Lee Schwartzberg, Hirotoshi Iihara, Matti Aapro, Richard Gralla
Supportive Care in Cancer. 2023-12-20
29 citations
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Puneeth Iyengar, Sean All, Mark F Berry, Thomas P Boike, Lisa Bradfield
Practical Radiation Oncology. 2023-04-25

Other

Characteristics of antiemetic drugs
Hesketh PJ, Longstreth GF
http://www.uptodate.com/contents/characteristics-of-antiemetic-drugs
UpToDate, Wolters Kluwer Health - 2013-02-18
Pathophysiology and prediction of chemotherapy-induced nausea and vomiting
Hesketh PJ
http://www.uptodate.com/contents/pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-v
UpToDate, Wolters Kluwer Health - 2012-10-01
Prevention and treatment of chemotherapy-induced nausea and vomiting
Hesketh PJ
http://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomitin
UpToDate, Wolters Kluwer Health - 2013-03-08

Press Mentions

Cancer Survivorship Program Goes the Extra MileJuly 18th, 2019
Management of Chemotherapy-Induced Nausea & VomitingDecember 10th, 2017
How to Succeed in Modernizing Clinical TrialsJanuary 10th, 2017
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member